Korean J Schizophr Res.  2014 Oct;17(2):93-99. 10.16946/kjsr.2014.17.2.93.

Variables Influencing Subjective Well-Being in Patients with Schizophrenia

• Oh J
• Ko YH
• Paik JW
• Lee MS
• Han C
• Jeong HG
• Ham BJ
• Kim YK
• Kim SH

• KMID: 2288293
• DOI: http://doi.org/10.16946/kjsr.2014.17.2.93

Abstract

OBJECTIVES
The purpose of this study was to analyze the relationship between subjective well-being and other clinical parameters such as sociodemographic and clinical variables, which include positive and negative symptoms, depressive symptoms, insight, and side effects.
METHODS
Fifty-one outpatients diagnosed with schizophrenia were recruited in this study. Subjective well-being was assessed using a self-rating scale, the Subjective Well-being under Neuroleptics-Short form (SWN-K). Sociodemographic variables were also evaluated and other evaluations were conducted using the Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS), Korean Version of the Revised Insight Scale for Psychosis (KISP), and Multidimensional Scale of Perceived Social Support (MSPSS). The relationship between subjective well-being and these clinical variables was assessed.
RESULTS
Education years and social support scores were positively correlated with the total SWN-K scores, but severity of illness, severity of depression, severity of side effect, and the scores on insight were negatively correlated. The stepwise multiple regression analyses indicated that the total SWN-K score of the patients with schizophrenia was associated with negative symptoms and insight.
CONCLUSION
Better insight and more severe negative symptoms in patients with schizophrenia may be associated with worse subjective well-being. Results indicate that careful evaluation of subjective well-being is essential for proper management of patients with schizophrenia.

Keyword

Schizophrenia; Subjective well-being; SWN-K; Insight; Negative symptom

MeSH Terms

Depression
Education
Humans
Outpatients
Psychotic Disorders
Schizophrenia*

Reference

References

1. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med. 1994; 330:681–690.

2. Karow A, Naber D. Subjective wellbeing and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl). 2002; 162:3–10.

3. Narvaez JM, Twamley EW, McKibbin CL, Heaton RK, Patterson TL. Subjective and objective quality of life in schizophrenia. Schizophr Res. 2008; 98:201–208.

4. Kim SW, Shin IS, Kim JM, Yoo JA, Ahn YM, Kwon JS, et al. A validation study of the korean version of the subjective wellbeing under neuroleptic treatment scale-short form. Korean J Psychopharmacol. 2007; 18:221–230.

5. Spilker B. Quality of life and pharmacoeconomics in clinical trials. 2nd ed.Philadelphia-New York: Lippincott-Raven;1996. p. 11–24.

6. Bullinger M, Hasford J. Evaluating quality-of-life measures for clinical trials in germany. Control Clin Trials. 1991; 12:91–105.

7. Lambert M, Schimmelmann BG, Schacht A, Karow A, Wagner T, Wehmeier PM, et al. Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years. Schizophr Res. 2009; 107:165–172.

8. Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res. 2007; 91:178–186.

9. Wehmeier PM, Kluge M, Schneider E, Schacht A, Wagner T, Schreiber W. Quality of life and subjective wellbeing during treatment with antipsychotics in outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31:703–712.

10. Lambert M, Naber D, Eich F, Schacht M, Linden M, Schimmelmann B. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand. 2007; 115:106–113.

11. Karow A, Czekalla J, Dittmann RW, Schacht A, Wagner T, Lambert M, et al. Association of subjective wellbeing, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry. 2007; 68:75–80.

12. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Cen-torrhino F, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006; 83:53–63.

13. Heslegrave RJ, Awad AG, Voruganti L. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neurosci. 1997; 22:235.

14. Lysaker PH, Davis LW, Warman DM, Strasburger A, Beattie N. Stigma, social function and symptoms in schizophrenia and schizoaffective disorder: associations across 6 months. Psychiatry Res. 2007; 149:89.

15. Galletly CA, Clark CR, McFarlane AC, Weber DL. Relationships between changes in symptom ratings, neuropsychological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res. 1997; 72:161–166.

16. Packer S, Husted J, Cohen S, Tomlinson G. Psychopathology and quality of life in schizophrenia. J Psychiatry Neurosci. 1997; 22:231.

17. Karow A, Moritz S, Lambert M, Schoder S, Krausz M. Panss syndromes and quality of life in schizophrenia. Psychopathology. 2005; 38:320–326.

18. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res. 2001; 51:171–180.

19. Kim JH, Ann JH, Kim MJ. The relationship between depressive symptoms and subjective wellbeing in newly admitted patients with schizophrenia. Compr Psychiatry. 2010; 51:165–170.

20. Dickerson F, Ringel N, Parente F. Subjective quality of life in outpatients with schizophrenia: clinical and utilization correlates. Acta Psychiatr Scand. 1998; 98:124–127.

21. Jung HY, Joo YH, Shin HK, Chung EK, Kang UG, Roh MS, et al. A validation study of korean-version of liverpool university neuroleptic side effect rating scale (LUNSERS): liverpool university neuroleptic side effect rating scale (LUNSERS). J Korean Neuropsychiatr Assoc. 2002; 41:138–145.

22. Ryu SH. Subjective quality of life in patients with schizophrenia receiving antipsychotics: relationship among subjective quality of life, drug attitude, and side-effect profiles of drugs. Korean J Psychopharmacol. 2005; 16:42–51.

23. Corrigan PW, Buican B. The construct validity of subjective quality of life for the severely mentally ill. J Nerv Ment Dis. 1995; 183:281–285.

24. Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis. 2003; 191:287–294.

25. Ritsner M, Modai I, Endicott J, Rivkin O, Nechamkin Y, Barak P, et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry. 2000; 61:880–889.

26. Alptekin K, Akvardar Y, Akdede BBK, Dumlu K, Işık D, Pirinçci F, et al. Is quality of life associated with cognitive impairment in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29:239–244.

27. Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32:280–287.

28. Karow A, Pajonk FG. Insight and quality of life in schizophrenia: recent findings and treatment implications. Curr Opin Psychiatry. 2006; 19:637–641.

29. Sim K, Mahendran R, Siris SG, Heckers S, Chong SA. Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res. 2004; 129:141.

30. Hasson-Ohayon I, Kravetz S, Roe D, David AS, Weiser M. Insight into psychosis and quality of life. Compr Psychiatry. 2006; 47:265–269.

31. Naber D, Moritz S, Lambert M, Rajonk F, Holzbach R, Mass R, et al. Improvement of schizophrenic patients'subjective wellbeing under atypical antipsychotic drugs. Schizophr Res. 2001; 50:79–88.

32. Yoon JS, Kook SH, Lee HY, Lee C, Paik IH. The development of a korean modification of the scale to measure subjective wellbeing under neuroleptic treatment (KmSWN). J Korean Neuropsychiatr Assoc. 2000; 39:987–998.

33. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995; 10:133–138.

34. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13:261–276.

35. Kay SR, Opler LA, Lindenmayer JP. The positive and negative syndrome scale (PANSS): Rationale and standardisation. Br J Psychiatry Suppl. 1989; 155:59–67.

36. Yi JS, Ahn YM, Shin HK, An SK, Joo YH, Kim SH, et al. Reliability and validity of the korean version of the positive and negative syndrome scale. J Korean Neuropsychiatr Assoc. 2001; 40:1090–1105.

37. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990; 3:247–251.

38. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992; 6:201–208.

39. Kim JH, Yim SJ, Yoon HJ. Assessing the reliability and validity of the korean version of the revised insight scale for psychosis (KISP). Schizophr Clinics. 2004; 7:15–21.

40. Hogan T, Awad A. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures. Psychol Med. 1992; 22:347–352.

41. Yoon BH, Bahk WM, Lee KU, Ahn JK, Kim MK. Psychometric properties of korean version of drug attitude inventory (KDAI-10). Korean J Psychopharmacol. 2005; 16:480–487.

42. Eker D, Arkar H. Perceived social support: Psychometric properties of the mspss in normal and pathological groups in a developing country. Soc Psychiatry Psychiatr Epidemiol. 1995; 30:121–126.

43. Cardoso CS, Caiaffa WT, Bandeira M, Siqueira AL, Abreu MNS, Fonseca JOP. Factors associated with low quality of life in schizophrenia. Cad Saude Publica. 2005; 21:1338–1340.

44. Röder-Wanner UU, Oliver JP, Priebe S. Does quality of life differ in schizophrenic women and men? An empirical study. Int J Soc Psychiatry. 1997; 43:129–143.

45. Koivumaa-Honkanen HT, Viinamäki H, Honkanen R, Tanskanen A, Antikainen R, Niskanen L, et al. Correlates of life satisfaction among psychiatric patients. Acta Psychiatr Scand. 1996; 94:372–378.

46. Huber G, Gross G, Schüttler R. A longterm follow-up study of schizophrenia: psychiatric course of illness and prognosis. Acta Psychiatr Scand. 1975; 52:49–57.

47. Cobb S. Presidential address-1976. Social support as a moderator of life stress. Psychosom Med. 1976; 38:300–314.

48. Yang DS, Kook SH, Choi Y, Lee HY. The relations among sociodemographic, clinical and psychological characteristics and quality of life in patients with psychotic disorders and their caregivers. J Korean Neuropsychiatr Assoc. 2001; 40:1044–1054.

49. Yoo HJ, Yoon DJ, Shin YW, Bahn G, Kim JW. Quality of life and insight in patients with schizophrenia. J Korean Neuropsychiatr Assoc. 1999; 38:340–348.

50. Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry. 1998; 155:1196–1201.

51. De Haan L, Weisfelt M, Dingemans P, Linszen D, Wouters L. Psychometric properties of the subjective wellbeing under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology (Berl). 2002; 162:24–28.

52. Kim KJ, Seol JH, Paik YS, Kim JH. The relationship between quality of life and psychosocial characteristics in patients with schizophrenia. J Korean Neuropsychiatr Assoc. 2004; 43:603–610.

53. Kim EK, Seo KR, Yoon CY. Effect of clozapine on the quality of life in treatment-resistant schizophrenic patients. J Korean Neuropsychiatr Assoc. 1999; 38:1447–1458.

54. Pinikahana J, Happell B, Hope J, Keks NA. Quality of life in schizophrenia: a review of the literature from 1995 to 2000. Int J Ment Health Nurs. 2002; 11:103–111.

55. Suh HS, Kim CH, Lee HS, Jung YC, Choi YH, Huh SY, et al. Quality of life and psychopathology in patients with schizophrenia: subjective and objective assessment. J Korean Neuropsychiatr Assoc. 2001; 40:1122–1131.